Profund Advisors LLC Sells 765 Shares of Zoetis Inc. (NYSE:ZTS)

Profund Advisors LLC trimmed its position in Zoetis Inc. (NYSE:ZTS) by 7.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,838 shares of the company’s stock after selling 765 shares during the period. Profund Advisors LLC’s holdings in Zoetis were worth $1,706,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of ZTS. Price T Rowe Associates Inc. MD lifted its holdings in shares of Zoetis by 31.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Sarasin & Partners LLP lifted its holdings in shares of Zoetis by 546.3% in the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock valued at $390,682,000 after purchasing an additional 1,904,899 shares in the last quarter. Swedbank AB bought a new stake in Zoetis during the first quarter worth about $210,815,000. Public Employees Retirement Association of Colorado bought a new stake in Zoetis during the fourth quarter worth about $242,757,000. Finally, CIBC Private Wealth Group LLC raised its holdings in Zoetis by 122.6% during the fourth quarter. CIBC Private Wealth Group LLC now owns 1,448,665 shares of the company’s stock worth $285,923,000 after acquiring an additional 797,884 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research upped their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Stifel Nicolaus upped their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Finally, Piper Sandler upped their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $220.38.

Zoetis Price Performance

Zoetis stock opened at $192.64 on Monday. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The stock’s 50 day moving average is $184.70 and its 200-day moving average is $174.33. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The company has a market capitalization of $87.90 billion, a price-to-earnings ratio of 37.12, a PEG ratio of 2.98 and a beta of 0.88.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.41 earnings per share. Equities research analysts expect that Zoetis Inc. will post 5.84 EPS for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.